Navigation Links
Agendia to Provide Testimony at Public Meeting on FDA Oversight of Laboratory-Developed Tests
Date:7/15/2010

IRVINE, California, and AMSTERDAM, July 15, 2010 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, announced today that company CEO Dr. Bernhard Sixt will provide testimony at a public meeting on July 20 in Washington D.C. on the federal regulation of laboratory developed tests (LDTs). Jointly organized by the Food and Drug Administration (FDA) and Center for Devices and Radiological Health (CDRH), the Public Meeting on Oversight of Laboratory Developed Tests will be a forum for key stakeholders, including laboratory professionals, clinicians, patients and industry leaders, to discuss and define the issues surrounding LDT regulation which pose the greatest risk to the public health. Dr. Sixt will present in Session II, "Oversight of LDTs: Clinical Laboratory Challenges."

Since the implementation of the 1976 Medical Device Amendments, the FDA has exercised enforcement discretion over LDTs, but has not pursued active regulation of the category. However, in recent years these tests have become increasingly complex and high risk in nature, and are playing an important role in clinical decision-making. As a result, the FDA has decided that LDTs which have not been properly validated put patients at risk, and that a risk-based application of oversight for the category is appropriate.

Agendia joins the FDA among other leading organizations, including Genentech, the College of American Pathologists, and the Genetics & Public Policy Center at Johns Hopkins University, in calling for a tiered risk-based approach to the regulation of LDTs. As the nation's leading authority for patient safety, Agendia believes that only the FDA can regulate the LDT category in a uniform and unbiased manner to ensure that all claims are validated, data is accurate and post-market surveillance is in place. Moreover, Agendia believes that holding the LDT category to the rigors of FDA scrutiny will inspire greater confidence among investors to enter this emerging market, foster a level playing field among molecular diagnostics companies and encourage the best technology to come to the fore in personalized medicine.

As the developer of the first and only FDA-cleared breast cancer recurrence test, MammaPrint, Agendia has led by example in the molecular diagnostics industry by embarking on a path of regulatory compliance. Agendia believes that patients and physicians deserve to be fully informed about the benefits and risks of medical diagnostics, and that all companies developing these devices should be held accountable for the claims and safety of their tests.

The FDA will collect and review all comments and information presented at this public meeting towards the development of a draft oversight framework for public comment. The meeting will be held on July 19 (8:00 a.m. to 5:00 p.m.) and July 20 (8:00 a.m. to 5:30 p.m.) at The Marriott Inn and Conference Center, University of Maryland University College.


'/>"/>
SOURCE Agendia B.V.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer
2. FDA Broadens Clearance for Agendias MammaPrint(R)
3. /C O R R E C T I O N -- Agendia B.V./
4. Agendias Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations
5. Agendias Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
6. Agendias MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
7. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
8. Agendias MammaPrint(R) Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines
9. Agendia Launches TargetPrint(R) for Breast Cancer Patients
10. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
11. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Divoti USA will engrave and process all non-coated ... latest FDA requirements, which stipulates new criteria regarding medical device manufacture ... Medical ID jewelry such as Medical ID Bracelets, can rest assured ... of the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving process ...
(Date:10/11/2017)... 11, 2017  Caris Life Sciences ® , a ... promise of precision medicine, today announced that St. Jude ... Oncology Alliance™ (POA) as its 17 th member. ... Jude Crosson Cancer Institute will help develop standards of ... tumor profiling, making cancer treatment more precise and effective. ...
(Date:10/10/2017)... COUNTY, Calif. , Oct. 10, 2017  NDS received FDA ... Mobile  — a medical-grade battery-powered display stand specifically designed for endoscopy ... to transform technology into a clinical solution to support the improvement ... Innovative Design ... ZeroWire Mobile Wireless Solution ...
Breaking Medicine Technology:
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards luncheon ... editorial and design excellence across a range of sectors. This year’s program included the ...
(Date:10/12/2017)... Wesley Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... Chapel is holding a treadmill relay – Miles by Moonlight to raise money for ... by donating $300 or more. , Teams will work together to keep their ...
(Date:10/12/2017)... ... , ... Health Literacy Innovations (HLI), creator of the Health ... Cancer Patient Education Network (CPEN), an independent professional organization that shares best practices ... , As CPEN’s strategic partner, HLI will help support CPEN members by ...
Breaking Medicine News(10 mins):